Connection

Lee Chao to Animals

This is a "connection" page, showing publications Lee Chao has written about Animals.
Connection Strength

1.509
  1. Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2018; 2018:4138560.
    View in: PubMed
    Score: 0.047
  2. Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. Oxid Med Cell Longev. 2017; 2017:5262958.
    View in: PubMed
    Score: 0.044
  3. Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017 11 27; 398(12):1309-1317.
    View in: PubMed
    Score: 0.044
  4. Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. Oxid Med Cell Longev. 2017; 2017:5025610.
    View in: PubMed
    Score: 0.043
  5. Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension. 2016 09; 68(3):533-41.
    View in: PubMed
    Score: 0.040
  6. Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res. 2014; 69:37-57.
    View in: PubMed
    Score: 0.033
  7. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest. 2013 May; 93(5):577-91.
    View in: PubMed
    Score: 0.032
  8. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 2012 Aug; 23(8):859-70.
    View in: PubMed
    Score: 0.030
  9. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010 Apr; 391(4):345-55.
    View in: PubMed
    Score: 0.026
  10. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.
    View in: PubMed
    Score: 0.023
  11. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007 Jul; 28(7):1383-9.
    View in: PubMed
    Score: 0.021
  12. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension. 2007 Mar; 49(3):490-7.
    View in: PubMed
    Score: 0.021
  13. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 2006 Dec; 17(12):1201-13.
    View in: PubMed
    Score: 0.020
  14. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006 Jun; 387(6):665-75.
    View in: PubMed
    Score: 0.020
  15. Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
    View in: PubMed
    Score: 0.020
  16. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol. 2006 Feb; 197(2):521-30.
    View in: PubMed
    Score: 0.019
  17. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes. 2005 May; 54(5):1573-80.
    View in: PubMed
    Score: 0.018
  18. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005 May; 90(3):291-8.
    View in: PubMed
    Score: 0.018
  19. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004 Dec; 15(12):1243-54.
    View in: PubMed
    Score: 0.018
  20. Adrenomedullin gene delivery inhibits neointima formation in rat artery after balloon angioplasty. Regul Pept. 2003 Apr 15; 112(1-3):115-20.
    View in: PubMed
    Score: 0.016
  21. Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats. Am J Physiol Regul Integr Comp Physiol. 2003 Apr; 284(4):R1031-6.
    View in: PubMed
    Score: 0.016
  22. Adenovirus-mediated gene transfer for cardiovascular and renal diseases. Methods Enzymol. 2002; 346:247-63.
    View in: PubMed
    Score: 0.015
  23. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides. 2001 Nov; 22(11):1731-7.
    View in: PubMed
    Score: 0.014
  24. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol. 2001 Jun; 280(6):F964-71.
    View in: PubMed
    Score: 0.014
  25. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem. 2001 Jan; 382(1):15-21.
    View in: PubMed
    Score: 0.014
  26. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000 Dec; 36(6):995-1001.
    View in: PubMed
    Score: 0.014
  27. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999 Oct 15; 44(1-2):57-65.
    View in: PubMed
    Score: 0.012
  28. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 Jun; 14(6):1376-84.
    View in: PubMed
    Score: 0.012
  29. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999 Jan; 33(1 Pt 2):219-24.
    View in: PubMed
    Score: 0.012
  30. Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice. J Am Heart Assoc. 2018 11 06; 7(21):e009562.
    View in: PubMed
    Score: 0.012
  31. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int. 1998 Oct; 54(4):1250-60.
    View in: PubMed
    Score: 0.012
  32. Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway. J Cell Mol Med. 2018 09; 22(9):4387-4398.
    View in: PubMed
    Score: 0.011
  33. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998 Jul 01; 9(10):1429-38.
    View in: PubMed
    Score: 0.011
  34. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998 Jan 01; 9(1):21-31.
    View in: PubMed
    Score: 0.011
  35. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997 Dec; 20(4):269-77.
    View in: PubMed
    Score: 0.011
  36. New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant. 1997 Aug; 12(8):1569-74.
    View in: PubMed
    Score: 0.011
  37. Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
    View in: PubMed
    Score: 0.011
  38. Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology. 1997 Jun; 36(2-3):229-36.
    View in: PubMed
    Score: 0.011
  39. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol. 1997 Jun; 75(6):750-6.
    View in: PubMed
    Score: 0.011
  40. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997 Jun; 35(6):517-22.
    View in: PubMed
    Score: 0.011
  41. Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway. Aging Cell. 2017 08; 16(4):837-846.
    View in: PubMed
    Score: 0.011
  42. Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. Biochem Biophys Res Commun. 1997 Feb 13; 231(2):494-8.
    View in: PubMed
    Score: 0.010
  43. High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens. 1996 Nov; 18(8):975-93.
    View in: PubMed
    Score: 0.010
  44. Identification and characterization of two promoters of rat kallikrein-binding protein gene. Biochim Biophys Acta. 1996 Jul 17; 1307(3):285-93.
    View in: PubMed
    Score: 0.010
  45. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther. 1996 May 20; 7(8):901-11.
    View in: PubMed
    Score: 0.010
  46. Tissue kallikrein inhibitors in mammals. Immunopharmacology. 1996 May; 32(1-3):67-72.
    View in: PubMed
    Score: 0.010
  47. High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. Immunopharmacology. 1996 May; 32(1-3):105-7.
    View in: PubMed
    Score: 0.010
  48. Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension. 1996 Mar; 27(3 Pt 2):491-4.
    View in: PubMed
    Score: 0.010
  49. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec; 26(6 Pt 1):847-53.
    View in: PubMed
    Score: 0.010
  50. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler. 1995 Dec; 376(12):705-13.
    View in: PubMed
    Score: 0.010
  51. Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
    View in: PubMed
    Score: 0.009
  52. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. Antimicrob Agents Chemother. 2015 Sep; 59(9):5619-30.
    View in: PubMed
    Score: 0.009
  53. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care. 2015 May 01; 19:200.
    View in: PubMed
    Score: 0.009
  54. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension. 1995 Apr; 25(4 Pt 2):715-9.
    View in: PubMed
    Score: 0.009
  55. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem. 1995 Jan 06; 270(1):451-5.
    View in: PubMed
    Score: 0.009
  56. Histopathology of lymphatic tissues in transgenic mice expressing human tissue kallikrein gene. Lab Invest. 1994 Nov; 71(5):680-7.
    View in: PubMed
    Score: 0.009
  57. Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc. 2014 Sep 18; 3(5):e001194.
    View in: PubMed
    Score: 0.009
  58. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics. 1994 Sep 15; 23(2):362-9.
    View in: PubMed
    Score: 0.009
  59. Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics. 1994 Sep 15; 23(2):370-8.
    View in: PubMed
    Score: 0.009
  60. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology. 2014 Jun; 142(2):216-26.
    View in: PubMed
    Score: 0.009
  61. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994 Feb; 23(2):236-43.
    View in: PubMed
    Score: 0.008
  62. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem. 1993 Nov 15; 268(32):24498-505.
    View in: PubMed
    Score: 0.008
  63. Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother. 2013 Nov; 57(11):5366-72.
    View in: PubMed
    Score: 0.008
  64. Regulation of kininogen gene expression and localization in the lung after monocrotaline-induced pulmonary hypertension in rats. Proc Soc Exp Biol Med. 1993 Jun; 203(2):243-50.
    View in: PubMed
    Score: 0.008
  65. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J. 2013; 77(8):2134-44.
    View in: PubMed
    Score: 0.008
  66. Screening of complementary DNA library using radiolabeled antigen. Methods Enzymol. 1993; 217:325-35.
    View in: PubMed
    Score: 0.008
  67. Molecular cloning and characterization of rKlk10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. Biochemistry. 1992 Nov 10; 31(44):10922-8.
    View in: PubMed
    Score: 0.008
  68. Specificity determinants of rat tissue kallikrein probed by site-directed mutagenesis. Protein Eng. 1992 Sep; 5(6):569-75.
    View in: PubMed
    Score: 0.008
  69. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012 Oct 15; 303(8):F1230-8.
    View in: PubMed
    Score: 0.008
  70. Comparative studies on P2 specificity of wild-type rat tissue kallikrein, Y99H:W215G mutant and tonin. Agents Actions Suppl. 1992; 38 ( Pt 1):59-65.
    View in: PubMed
    Score: 0.007
  71. Localization of kallikrein gene family proteases in rat tissues. Agents Actions Suppl. 1992; 38 ( Pt 1):595-602.
    View in: PubMed
    Score: 0.007
  72. Expression of kallikrein-binding protein and alpha 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl. 1992; 38 ( Pt 1):174-81.
    View in: PubMed
    Score: 0.007
  73. Evolution of the kallikrein gene family. Agents Actions Suppl. 1992; 38 ( Pt 1):26-33.
    View in: PubMed
    Score: 0.007
  74. Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. Biochim Biophys Acta. 1991 Dec 02; 1129(1):127-30.
    View in: PubMed
    Score: 0.007
  75. Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem. 1991 Aug 25; 266(24):16029-36.
    View in: PubMed
    Score: 0.007
  76. Purification and characterization of recombinant tissue kallikrein from Escherichia coli and yeast. Biochem J. 1991 May 15; 276 ( Pt 1):63-71.
    View in: PubMed
    Score: 0.007
  77. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990 Sep 25; 265(27):16394-401.
    View in: PubMed
    Score: 0.007
  78. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010 Nov; 299(5):H1419-27.
    View in: PubMed
    Score: 0.007
  79. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 2010 Aug; 56(2):260-7.
    View in: PubMed
    Score: 0.007
  80. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer. 2010 May 31; 10:245.
    View in: PubMed
    Score: 0.007
  81. Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 2010 Apr; 298(4):F1033-40.
    View in: PubMed
    Score: 0.006
  82. Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol. 2010 Mar; 298(3):H1048-54.
    View in: PubMed
    Score: 0.006
  83. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S7-16.
    View in: PubMed
    Score: 0.006
  84. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens. 1989 Nov; 7(11):865-71.
    View in: PubMed
    Score: 0.006
  85. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
    View in: PubMed
    Score: 0.006
  86. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009 Sep; 297(3):H1040-7.
    View in: PubMed
    Score: 0.006
  87. Characterization of genes encoding rat tonin and a kallikrein-like serine protease. Biochemistry. 1989 Jun 27; 28(13):5334-43.
    View in: PubMed
    Score: 0.006
  88. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther. 2009 Feb; 20(2):147-58.
    View in: PubMed
    Score: 0.006
  89. Structural analysis of a rat renal kallikrein gene. Adv Exp Med Biol. 1989; 247A:73-80.
    View in: PubMed
    Score: 0.006
  90. Sex dimorphism and estrogen regulation of kininogens in rat serum, adrenal gland and kidney. Adv Exp Med Biol. 1989; 247B:297-303.
    View in: PubMed
    Score: 0.006
  91. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1735-43.
    View in: PubMed
    Score: 0.006
  92. Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry. 1988 Sep 20; 27(19):7189-96.
    View in: PubMed
    Score: 0.006
  93. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest. 2008 Nov; 88(11):1157-66.
    View in: PubMed
    Score: 0.006
  94. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res. 2008 Dec 01; 80(3):354-64.
    View in: PubMed
    Score: 0.006
  95. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
    View in: PubMed
    Score: 0.006
  96. A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J Hypertens. 1988 Jul; 6(7):551-7.
    View in: PubMed
    Score: 0.006
  97. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
    View in: PubMed
    Score: 0.006
  98. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008 May; 51(5):1358-65.
    View in: PubMed
    Score: 0.006
  99. Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim Biophys Acta. 1988 Mar 17; 964(3):329-39.
    View in: PubMed
    Score: 0.006
  100. Circulating autoantibodies to mammalian tissue kallikreins. Proc Soc Exp Biol Med. 1988 Mar; 187(3):320-6.
    View in: PubMed
    Score: 0.006
  101. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci. 2008 Apr; 102(2):433-43.
    View in: PubMed
    Score: 0.006
  102. Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays. Mol Cell Endocrinol. 1988 Jan; 55(1):21-31.
    View in: PubMed
    Score: 0.006
  103. Identification and expression of kallikrein gene family in rat submandibular and prostate glands using monoclonal antibodies as specific probes. Biochim Biophys Acta. 1987 Dec 08; 910(3):233-9.
    View in: PubMed
    Score: 0.005
  104. Identification of tonin in brain and exocrine tissues and in the cell-free translation products encoded by the mRNA of these tissues. Biochem J. 1987 Dec 01; 248(2):477-81.
    View in: PubMed
    Score: 0.005
  105. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008 Jan 16; 82(3-4):156-65.
    View in: PubMed
    Score: 0.005
  106. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol. 2007 Nov; 34(11):2171-6.
    View in: PubMed
    Score: 0.005
  107. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail. 2007 Sep; 13(7):588-96.
    View in: PubMed
    Score: 0.005
  108. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May; 148(5):2016-26.
    View in: PubMed
    Score: 0.005
  109. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept. 2007 Apr 05; 140(1-2):12-20.
    View in: PubMed
    Score: 0.005
  110. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res. 2007 Jan 01; 73(1):130-42.
    View in: PubMed
    Score: 0.005
  111. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther. 2006 May; 17(5):545-55.
    View in: PubMed
    Score: 0.005
  112. Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F567-77.
    View in: PubMed
    Score: 0.005
  113. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr; 47(4):752-61.
    View in: PubMed
    Score: 0.005
  114. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb; 17(2):206-19.
    View in: PubMed
    Score: 0.005
  115. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
    View in: PubMed
    Score: 0.005
  116. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F622-31.
    View in: PubMed
    Score: 0.005
  117. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 2005 Apr 08; 76(21):2457-71.
    View in: PubMed
    Score: 0.005
  118. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 2005 Apr; 52(4):1319-24.
    View in: PubMed
    Score: 0.005
  119. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
    View in: PubMed
    Score: 0.004
  120. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004 Aug; 66(2):722-32.
    View in: PubMed
    Score: 0.004
  121. Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats. J Gene Med. 2004 Jul; 6(7):786-97.
    View in: PubMed
    Score: 0.004
  122. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb; 43(2):452-9.
    View in: PubMed
    Score: 0.004
  123. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension. 2004 Jan; 43(1):109-16.
    View in: PubMed
    Score: 0.004
  124. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov; 42(5):1026-33.
    View in: PubMed
    Score: 0.004
  125. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1479-88.
    View in: PubMed
    Score: 0.004
  126. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003 Oct; 285(4):H1506-14.
    View in: PubMed
    Score: 0.004
  127. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol. 2003 06; 284(6):C1604-13.
    View in: PubMed
    Score: 0.004
  128. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2002 Aug 01; 22(8):1279-85.
    View in: PubMed
    Score: 0.004
  129. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001 Nov; 159(5):1797-805.
    View in: PubMed
    Score: 0.004
  130. Identification of a major heparin-binding site in kallistatin. J Biol Chem. 2001 Jan 12; 276(2):1276-84.
    View in: PubMed
    Score: 0.003
  131. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther. 2000 Sep 01; 11(13):1817-27.
    View in: PubMed
    Score: 0.003
  132. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension. 2000 Sep; 36(3):364-70.
    View in: PubMed
    Score: 0.003
  133. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
    View in: PubMed
    Score: 0.003
  134. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res. 2000 Mar 03; 86(4):418-24.
    View in: PubMed
    Score: 0.003
  135. Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol. 2000 Mar; 278(3):F484-91.
    View in: PubMed
    Score: 0.003
  136. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
    View in: PubMed
    Score: 0.003
  137. Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology. 1999 Oct 15; 44(1-2):137-43.
    View in: PubMed
    Score: 0.003
  138. Kallikrein-binding protein is induced by growth hormone in the dwarf rat. FASEB J. 1999 Oct; 13(13):1839-44.
    View in: PubMed
    Score: 0.003
  139. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
    View in: PubMed
    Score: 0.003
  140. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
    View in: PubMed
    Score: 0.003
  141. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999 Aug; 34(2):164-70.
    View in: PubMed
    Score: 0.003
  142. Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol. 1999 03; 276(3):F476-84.
    View in: PubMed
    Score: 0.003
  143. Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta. 1998 Nov 08; 1442(2-3):177-85.
    View in: PubMed
    Score: 0.003
  144. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998 May; 53(5):1305-13.
    View in: PubMed
    Score: 0.003
  145. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998 May; 31(5):1104-10.
    View in: PubMed
    Score: 0.003
  146. Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun. 1998 Mar 17; 244(2):449-54.
    View in: PubMed
    Score: 0.003
  147. Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat. Am J Physiol. 1997 11; 273(5):F783-9.
    View in: PubMed
    Score: 0.003
  148. Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
    View in: PubMed
    Score: 0.003
  149. Molecular cloning and expression of rat kallistatin gene. Biochim Biophys Acta. 1997 Sep 12; 1353(3):277-86.
    View in: PubMed
    Score: 0.003
  150. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997 Sep; 30(3 Pt 1):307-13.
    View in: PubMed
    Score: 0.003
  151. Tissue-specific expression and promoter analyses of the human tissue kallikrein gene in transgenic mice. Biochem J. 1997 Jul 01; 325 ( Pt 1):111-6.
    View in: PubMed
    Score: 0.003
  152. Expression of human tissue kallikrein in rat salivary glands and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmacology. 1997 Jun; 36(2-3):221-7.
    View in: PubMed
    Score: 0.003
  153. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 1997 Mar; 38(3):658-64.
    View in: PubMed
    Score: 0.003
  154. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther. 1997 Feb 10; 8(3):341-7.
    View in: PubMed
    Score: 0.003
  155. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension. 1997 Jan; 29(1 Pt 2):488-93.
    View in: PubMed
    Score: 0.003
  156. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci. 1997; 60(17):1431-5.
    View in: PubMed
    Score: 0.003
  157. Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem. 1996 Nov 01; 271(44):27590-4.
    View in: PubMed
    Score: 0.003
  158. High-salt diet upregulates kininogen and downregulates tissue kallikrein expression in Dahl-SS and SHR rats. Am J Physiol. 1996 Oct; 271(4 Pt 2):F824-30.
    View in: PubMed
    Score: 0.003
  159. Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol. 1996 Jul; 271(1 Pt 2):F78-86.
    View in: PubMed
    Score: 0.002
  160. Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Biochem Biophys Res Commun. 1995 Dec 05; 217(1):113-22.
    View in: PubMed
    Score: 0.002
  161. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995 Apr; 95(4):1710-6.
    View in: PubMed
    Score: 0.002
  162. Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene. 1994 Nov 18; 149(2):283-8.
    View in: PubMed
    Score: 0.002
  163. Molecular cloning and sequence analysis of rat bradykinin B2 receptor gene. Biochim Biophys Acta. 1994 Sep 13; 1219(1):171-4.
    View in: PubMed
    Score: 0.002
  164. Expression and characterization of rat kallikrein-binding protein in Escherichia coli. Biochem J. 1993 Jun 15; 292 ( Pt 3):825-32.
    View in: PubMed
    Score: 0.002
  165. Biochemical characterization and substrate specificity of rat prostate kallikrein (S3): comparison with tissue kallikrein, tonin and T-kininogenase. Biochim Biophys Acta. 1992 Jun 24; 1121(3):309-16.
    View in: PubMed
    Score: 0.002
  166. Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim Biophys Acta. 1992 Jun 15; 1131(2):145-51.
    View in: PubMed
    Score: 0.002
  167. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med. 1992 May; 119(5):514-21.
    View in: PubMed
    Score: 0.002
  168. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 1992 Apr; 41(4):789-95.
    View in: PubMed
    Score: 0.002
  169. Molecular cloning and primary structure of rat alpha 1-antitrypsin. Biochemistry. 1990 Jan 16; 29(2):323-9.
    View in: PubMed
    Score: 0.002
  170. Co-localization of a kallikrein-like serine protease (arginine esterase A) and atrial natriuretic peptide in rat atrium. J Histochem Cytochem. 1989 Dec; 37(12):1913-7.
    View in: PubMed
    Score: 0.002
  171. Sex dimorphism and inflammatory regulation of T-kininogen and T-kininogenase. Biochim Biophys Acta. 1989 Jun 27; 991(3):477-83.
    View in: PubMed
    Score: 0.002
  172. Renal kallikrein mRNA localization by in situ hybridization. Kidney Int. 1989 Jun; 35(6):1324-9.
    View in: PubMed
    Score: 0.002
  173. Enhanced specificity in immunoscreening of expression cDNA clones using radiolabeled antigen overlay. Biotechniques. 1989 Jan; 7(1):68-72.
    View in: PubMed
    Score: 0.001
  174. Comparison of the distribution of tissue kallikrein and esterase A, a kallikrein-like enzyme, in rat kidney using specific monoclonal antibodies. J Histochem Cytochem. 1988 Oct; 36(10):1251-4.
    View in: PubMed
    Score: 0.001
  175. Immunocytochemical localization of a kallikrein-like serine protease (esterase A) in rat salivary glands. Anat Rec. 1988 May; 221(1):475-81.
    View in: PubMed
    Score: 0.001
  176. Identification and characterization of a tissue kallikrein in rat skeletal muscles. Biochem J. 1987 May 01; 243(3):773-8.
    View in: PubMed
    Score: 0.001
  177. Sperm and seminal plasma antigens from autoimmune men induce immunological infertility. Arch Androl. 1987; 19(2):161-75.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.